Electric field responsive nanotransducers for glioblastoma.

Akhil Jain, Isobel Jobson, Michaela Griffin, Ruman Rahman, Stuart Smith, Frankie J Rawson
{"title":"Electric field responsive nanotransducers for glioblastoma.","authors":"Akhil Jain,&nbsp;Isobel Jobson,&nbsp;Michaela Griffin,&nbsp;Ruman Rahman,&nbsp;Stuart Smith,&nbsp;Frankie J Rawson","doi":"10.1186/s42234-022-00099-7","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Electric field therapies such as Tumor Treating Fields (TTFields) have emerged as a bioelectronic treatment for isocitrate dehydrogenase wild-type and IDH mutant grade 4 astrocytoma Glioblastoma (GBM). TTFields rely on alternating current (AC) electric fields (EF) leading to the disruption of dipole alignment and induced dielectrophoresis (DEP) during cytokinesis. Although TTFields have a favourable side effect profile, particularly compared to cytotoxic chemotherapy, survival benefits remain limited (~ 4.9 months) after an extensive treatment regime (20 hours/day for 18 months). The cost of the technology also limits its clinical adoption worldwide. Therefore, the discovery of new technology that can enhance both the therapeutic efficiency and efficacy of these TTFields will be of great benefit to cancer treatment and decrease healthcare costs worldwide.</p><p><strong>Methods: </strong>In this work, we report the role of electrically conductive gold (GNPs), dielectric silica oxide (SiO<sub>2</sub>), and semiconductor zinc oxide (ZnO) nanoparticles (NPs) as transducers for enhancing EF mediated anticancer effects on patient derived GBM cells. Physicochemical properties of these NPs were analyzed using spectroscopic, electron microscopy, and light-scattering techniques.</p><p><strong>Results: </strong>In vitro TTFields studies indicated an enhanced reduction in the metabolic activity of patient-derived Glioma INvasive marginal (GIN 28) and Glioma contrast enhanced core (GCE 28) GBM As per our journal style, article titles should not include capitalised letters unless these are proper nouns/acronyms. We have therefore used the article title \"Electric field responsive nanotransducers for glioblastoma\" as opposed to \"Electric Field Responsive Nanotransducers for Glioblastoma\" as given in the submission system. Please check if this is correct.cells in groups treated with NPs vs. control groups, irrespective of NPs dielectric properties. Our results indicate the inorganic NPs used in this work enhance the intracellular EF effects that could be due to the virtue of bipolar dielectrophoretic and electrophoretic effects.</p><p><strong>Conclusions: </strong>This work presents preliminary evidence which could help to improve future EF applications for bioelectronic medicine. Furthermore, the merits of spherical morphology, excellent colloidal stability, and low toxicity, make these NPs ideal for future studies for elucidating the detailed mechanism and efficacy upon their delivery in GBM preclinical models.</p>","PeriodicalId":72363,"journal":{"name":"Bioelectronic medicine","volume":" ","pages":"17"},"PeriodicalIF":0.0000,"publicationDate":"2022-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9580136/pdf/","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bioelectronic medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s42234-022-00099-7","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 4

Abstract

Background: Electric field therapies such as Tumor Treating Fields (TTFields) have emerged as a bioelectronic treatment for isocitrate dehydrogenase wild-type and IDH mutant grade 4 astrocytoma Glioblastoma (GBM). TTFields rely on alternating current (AC) electric fields (EF) leading to the disruption of dipole alignment and induced dielectrophoresis (DEP) during cytokinesis. Although TTFields have a favourable side effect profile, particularly compared to cytotoxic chemotherapy, survival benefits remain limited (~ 4.9 months) after an extensive treatment regime (20 hours/day for 18 months). The cost of the technology also limits its clinical adoption worldwide. Therefore, the discovery of new technology that can enhance both the therapeutic efficiency and efficacy of these TTFields will be of great benefit to cancer treatment and decrease healthcare costs worldwide.

Methods: In this work, we report the role of electrically conductive gold (GNPs), dielectric silica oxide (SiO2), and semiconductor zinc oxide (ZnO) nanoparticles (NPs) as transducers for enhancing EF mediated anticancer effects on patient derived GBM cells. Physicochemical properties of these NPs were analyzed using spectroscopic, electron microscopy, and light-scattering techniques.

Results: In vitro TTFields studies indicated an enhanced reduction in the metabolic activity of patient-derived Glioma INvasive marginal (GIN 28) and Glioma contrast enhanced core (GCE 28) GBM As per our journal style, article titles should not include capitalised letters unless these are proper nouns/acronyms. We have therefore used the article title "Electric field responsive nanotransducers for glioblastoma" as opposed to "Electric Field Responsive Nanotransducers for Glioblastoma" as given in the submission system. Please check if this is correct.cells in groups treated with NPs vs. control groups, irrespective of NPs dielectric properties. Our results indicate the inorganic NPs used in this work enhance the intracellular EF effects that could be due to the virtue of bipolar dielectrophoretic and electrophoretic effects.

Conclusions: This work presents preliminary evidence which could help to improve future EF applications for bioelectronic medicine. Furthermore, the merits of spherical morphology, excellent colloidal stability, and low toxicity, make these NPs ideal for future studies for elucidating the detailed mechanism and efficacy upon their delivery in GBM preclinical models.

Abstract Image

Abstract Image

Abstract Image

用于胶质母细胞瘤的电场响应纳米传感器。
背景:电场疗法如肿瘤治疗电场(TTFields)已经成为异柠檬酸脱氢酶野生型和IDH突变型4级星形细胞瘤胶质母细胞瘤(GBM)的生物电子治疗方法。TTFields依赖于交流电(AC)电场(EF)导致偶极子排列的破坏和细胞分裂期间诱导的介电电泳(DEP)。尽管TTFields具有良好的副作用,特别是与细胞毒性化疗相比,但在广泛的治疗方案(每天20小时,持续18个月)后,生存获益仍然有限(约4.9个月)。该技术的成本也限制了其在全球范围内的临床应用。因此,能够提高这些TTFields的治疗效率和疗效的新技术的发现将对癌症治疗和降低全球医疗保健成本有很大的好处。方法:在这项工作中,我们报道了导电金(GNPs)、介电二氧化硅(SiO2)和半导体氧化锌(ZnO)纳米颗粒(NPs)作为换能器在增强EF介导的患者源性GBM细胞抗癌作用中的作用。利用光谱学、电子显微镜和光散射技术分析了这些NPs的物理化学性质。结果:体外TTFields研究表明,患者源性胶质瘤侵袭性边缘(GIN 28)和胶质瘤对比增强核心(GCE 28) GBM的代谢活性增强降低。根据我们的期刊风格,文章标题不应包括大写字母,除非这些是专有名词/首字母缩写。因此,我们使用了文章标题“用于胶质母细胞瘤的电场响应纳米换能器”,而不是提交系统中给出的“用于胶质母细胞瘤的电场响应纳米换能器”。请检查这是否正确。NPs处理组与对照组的细胞,不考虑NPs的介电性质。我们的研究结果表明,在这项工作中使用的无机NPs增强了细胞内的EF效应,这可能是由于双极介电和电泳效应的优点。结论:本工作提供了初步的证据,有助于提高未来EF在生物电子医学中的应用。此外,球形形态、优异的胶体稳定性和低毒性的优点使这些NPs成为未来研究阐明其在GBM临床前模型中递送的详细机制和功效的理想选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.90
自引率
0.00%
发文量
0
审稿时长
8 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信